FLT3/ABL/Aurora Kinase Inhibitor KW-2449

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116858

841258-76-2

C116858

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

CTRP

GDC

FDA

An orally available inhibitor of FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), the tyrosine kinase ABL, and aurora kinases, with potential antineoplastic activity. Upon administration, FLT3/ABL/Aurora kinase inhibitor KW-2449 specifically binds to and inhibits both wild-type and mutated forms of FLT3, ABL and aurora kinases, which both interferes with the activation of signal transduction pathways mediated by these kinases and reduces the proliferation of susceptible cancer cells. FLT3 and ABL kinases are upregulated in certain tumor cells and play important roles in tumor cell proliferation and metastasis. Aurora kinases, serine-threonine kinases overexpressed by a wide variety of cancer cell types, play essential roles in mitotic checkpoint control.

FLT3/ABL/Aurora Kinase Inhibitor KW-2449

2D9N67F58G

FLT3/ABL/Aurora Kinase Inhibitor KW-2449

KW-2449

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

FLT3/ABL/Aurora Kinase Inhibitor KW-2449

FLT3/ABL/Aurora Kinase Inhibitor KW-2449

496931

496931

496931

FLT3/ABL/Aurora Kinase Inhibitor KW-2449

Thesaurus:C116858

FLT3/ABL/Aurora Kinase Inhibitor KW-2449

Pharmacologic Substance

C1831922

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1404

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129825